Natural killer (NK) cells are major players of the innate immune system. They play a central role in immune surveillance and early immune responses to cancer and infection. NK cells might be explored as a tool for treatment of malignant disease in both transplant and non-transplant settings.
The use of specific CliniMACS® Product Lines allows GMP-compliant manufacturing of NK cell products according to the needs given by a specific treatment concept.
Highly enriched NK cell products are generated by CD3 depletion followed by CD56 enrichment. A combined NK cell and natural killer T (NKT) cell product is produced by a single CD56 enrichment step. Heterogeneous NK cell products can be manufactured by either CD3 or TCRα/β depletion, optionally in combination with CD19 depletion if B cell depletion is required. The latter two manufacturing strategies for NK cells allow co-enrichment of NK cells and accessory cells, such as monocytes and dendritic cells (DCs). In case of TCRα/β depletion, γ/δ T cells are also preserved within the NK cell product, and, potentially, this could have a clinical add-on value.